Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA-4948 for the Treatment of Anemia in Patients With Lower Risk MDS
NCT05178342Phase 2Terminated
- Sponsor
- Leipzig University
- Start
- Jan 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of emavusertib in myelodysplastic syndrome (MDS), anemia, sponsored by Leipzig University. Started Jan 2022; status: terminated.
02
Drugs
emavusertib
03
Conditions
myelodysplastic syndrome (MDS)anemia
Beyond the preview
Go deeper on NCT05178342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05178342.